Lung cancer in HIV-infected patients in the combination antiretroviral treatment era

José Moltó; Teresa Moran; Guillem Sirera; Bonaventura Clotet

doi:10.3978/j.issn.2218-6751.2015.08.10

Lung cancer in HIV-infected patients in the combination antiretroviral treatment era

José Moltó, Teresa Moran^*, Guillem Sirera, Bonaventura Clotet

^*Autor corresponent d’aquest treball

Departament de Medicina

Producció científica: Contribució a revista › Article de revisió › Recerca › Avaluat per experts

18 Cites (Scopus)

Resum

The advent of combination antiretroviral treatment (cART) has been followed by a decrease in HIV-associated morbidity and mortality, but also by an apparent increase in the incidence of non-AIDSdefining cancers (NADCs). The risk of lung cancer is substantially higher in HIV-infected patients than in the general population, in part due to aging and tobacco use, and it is the most frequent NADC. The management of lung cancer in HIV-infected patients has some peculiarities that need to be taken into account. This review focuses on the epidemiology, risk factors, and clinical management of lung cancer in HIV-infected patients. In addition, screening tools and future perspectives are also discussed.

Idioma original	Anglès
Pàgines (de-a)	678-688
Nombre de pàgines	11
Revista	Translational Lung Cancer Research
Volum	4
Número	6
DOIs	https://doi.org/10.3978/j.issn.2218-6751.2015.08.10
Estat de la publicació	Publicada - 28 de des. 2015

SDG de les Nacions Unides

Aquest resultat contribueix als següents objectius de desenvolupament sostenible.

Accés al document

10.3978/j.issn.2218-6751.2015.08.10Llicència: Creative Commons Reconeixement sense Obra Derivada

Altres arxius i enllaços

Enllaç a la publicació de Scopus

Com citar-ho

@article{05bb5cdca007483bbda809d7ca013a59,

title = "Lung cancer in HIV-infected patients in the combination antiretroviral treatment era",

abstract = "The advent of combination antiretroviral treatment (cART) has been followed by a decrease in HIV-associated morbidity and mortality, but also by an apparent increase in the incidence of non-AIDSdefining cancers (NADCs). The risk of lung cancer is substantially higher in HIV-infected patients than in the general population, in part due to aging and tobacco use, and it is the most frequent NADC. The management of lung cancer in HIV-infected patients has some peculiarities that need to be taken into account. This review focuses on the epidemiology, risk factors, and clinical management of lung cancer in HIV-infected patients. In addition, screening tools and future perspectives are also discussed.",

keywords = "Antiretroviral treatment, HIV infection, Lung cancer, Non-AIDS-defining cancers (NADCs)",

author = "Jos{\'e} Molt{\'o} and Teresa Moran and Guillem Sirera and Bonaventura Clotet",

note = "Publisher Copyright: {\textcopyright} Translational lung cancer research.",

year = "2015",

month = dec,

day = "28",

doi = "10.3978/j.issn.2218-6751.2015.08.10",

language = "English",

volume = "4",

pages = "678--688",

journal = "Translational Lung Cancer Research",

issn = "2218-6751",

publisher = "Society for Translational Medicine (STM)",

number = "6",

}

TY - JOUR

T1 - Lung cancer in HIV-infected patients in the combination antiretroviral treatment era

AU - Moltó, José

AU - Moran, Teresa

AU - Sirera, Guillem

AU - Clotet, Bonaventura

N1 - Publisher Copyright: © Translational lung cancer research.

PY - 2015/12/28

Y1 - 2015/12/28

N2 - The advent of combination antiretroviral treatment (cART) has been followed by a decrease in HIV-associated morbidity and mortality, but also by an apparent increase in the incidence of non-AIDSdefining cancers (NADCs). The risk of lung cancer is substantially higher in HIV-infected patients than in the general population, in part due to aging and tobacco use, and it is the most frequent NADC. The management of lung cancer in HIV-infected patients has some peculiarities that need to be taken into account. This review focuses on the epidemiology, risk factors, and clinical management of lung cancer in HIV-infected patients. In addition, screening tools and future perspectives are also discussed.

AB - The advent of combination antiretroviral treatment (cART) has been followed by a decrease in HIV-associated morbidity and mortality, but also by an apparent increase in the incidence of non-AIDSdefining cancers (NADCs). The risk of lung cancer is substantially higher in HIV-infected patients than in the general population, in part due to aging and tobacco use, and it is the most frequent NADC. The management of lung cancer in HIV-infected patients has some peculiarities that need to be taken into account. This review focuses on the epidemiology, risk factors, and clinical management of lung cancer in HIV-infected patients. In addition, screening tools and future perspectives are also discussed.

KW - Antiretroviral treatment

KW - HIV infection

KW - Lung cancer

KW - Non-AIDS-defining cancers (NADCs)

UR - https://www.scopus.com/pages/publications/84960118290

U2 - 10.3978/j.issn.2218-6751.2015.08.10

DO - 10.3978/j.issn.2218-6751.2015.08.10

M3 - Review article

SN - 2218-6751

VL - 4

SP - 678

EP - 688

JO - Translational Lung Cancer Research

JF - Translational Lung Cancer Research

IS - 6

ER -

Lung cancer in HIV-infected patients in the combination antiretroviral treatment era

Resum

SDG de les Nacions Unides

Accés al document

Altres arxius i enllaços

Fingerprint

Com citar-ho